- $177.44m
- $62.41m
- $6.39m
Brief: Frequency Therapeutics Reports Final Results From Four-Arm, Phase 2A Study Of FX-322
U.S. RESEARCH ROUNDUP- Amgen, Lion Electric, UiPath
Frequency Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Frequency Therapeutics: Falls as Q1 net loss widens, revenue misses
Brief: Frequency Therapeutics - Q1 Revenue Of $4.7 Mln
Brief: Frequency Therapeutics Provides Business Updates And Reports Q4 And Full Year 2020 Financial Results
U.S. RESEARCH ROUNDUP- Adobe, Intel, Wingstop
Frequency Therapeutics: JPM double downgrades as hearing loss trial disappoints
U.S. STOCKS ON THE MOVE-Baidu, Exagen, Hoth Therapeutics, Netflix
U.S. STOCKS ON THE MOVE-Baidu, Ionis Pharmaceuticals, ViacomCBS, Netflix
Frequency Therapeutics plunges as hearing loss treatment disappoints in mid-stage trial
Brief: Frequency Therapeutics Releases New Data From Two FX-322 Clinical Studies Plans To Advance Single-Dose Regimen
Brief: Frequency Therapeutics Reports Publication Of Data Showing Hearing Improvements In Patients Receiving FX-322
U.S. RESEARCH ROUNDUP- Coca-Cola, Galapagos, Under Armour
U.S. RESEARCH ROUNDUP- JetBlue Airways, Twitter, Zynga
Brief: Frequency Therapeutics - Effective As Of December 11, Entered Into Loan And Security Agreement
Brief: Frequency Therapeutics Appoints Peter Pfreundschuh As Chief Financial Officer
Brief: Frequency Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million
Brief: Frequency Therapeutics Reports Q3 Loss Per Share $0.16